ExoSurge: Future advances curing Peyronie’s Disease
Latest Peyronie’s Surgery Advances
Peyronie’s plication surgery (Nesbitt procedure) has long been recognized as the best Peyronie’s surgery pathway in regards to minimal post-surgical complications. Plication surgery is considered one of the Peyronie’s treatment successes. Incision and graft procedures have a history of causing ED, lost sensation and eventual Peyronie’s recurrence. Unfortunately, plication procedures often result in an equally devastating outcome for many patients: loss of erect penile length.
To qualify, Peyronie’s cases indicated for surgery must have curvature significant enough to severely impair sexual function. The downside of this approach is that it means such cases almost always have large amounts of dense tissue.
Find out how to heal from Peyronie’s
NCALXTM Decalcification Technology
Our urologists recently innovated a new, additional therapeutic for decalcification we’ve branded as “NCALX” that’s dramatically reduced the time associated with resolving cases with lots of calcified plaque.
The NCALX therapy is most often employed soon after a handful of ExoSurge® treatments that first soften and destabilize the calcified plaque. No cases in our retrospective study included the use of NCALX technology as its very new.
We hope to refine and improve the NCALX technology and related protocols so it can be included with our core ExoSurge® technology launch.
Venous Leak Repair
Approximately twenty-five percent of our treated Peyronie’s patients exhibit varying levels of venous leakage based upon patient interviews and results derived from duplex Doppler sonographic testing. Venous leakage is the inability to keep blood in the corpora long enough to enjoy a prolonged erection. While treating erectile dysfunction is not essential for Peyronie’s treatment, most patients want to perform well after the plaque is removed.
We offer Li-ESWT as a treatment option for venous leakage as it relates to improved performance with erectile dysfunction when indicated from patient reporting and sonogram analysis. Our sonogram testing reveals readings every five minutes for thirty minutes on both the left and right PSV (Peak Systolic Volume) and EDV (End Diastolic Volume). We consider an EDV reading above 10 to be a severe venous leak, mild to moderate is measured by a 5 to10 EDV grade. Anything below 5 is considered good and no treatment is recommended.
Additionally, we patented a new tandem of using Li-ESWT treatments in tandem with external counterpulsation (ECP) therapy that’s showing lots of promise for patients with severe venous leak whose only previous options for success were PGE injections or installation of a prosthetic implant. This latter technology is still under development.